This trial is testing the safety of Anti-SLAMF7 CAR-T cells in myeloma. The Anti-SLAMF7 CAR-T cells in this trial are altered to include a ‘stop switch’, to help limit toxicity of this therapy.
This trial is currently open and accepting patients.
This Phase 1 trial is being run in two different arms, dose escalation and dose expansion. It is non-randomized, with sequential assignment, which means that the dose you receive, or the trial arm you enroll in, depend on when you join the trial. It is also open label, which means that both the researchers and you will know which dose you are receiving, or arm you are participating in.
If patients develop bad side effects from the Anti-SLAMF7, researchers can decide to give them Rimiducid by intravenous infusion to cause cell death of the Anti-SLAMF7 CAR-T cells.
Enrollment: 42 patients (estimated)View More
The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required. Create your account or call us today for help (888) 828-2206.
View all clinical trial locations sorted by state.
Read the latest news and updates on this trial.
If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.
You can explore trial locations from around the US and connect directly with a trial coordinator.Find Nearby Locations
You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.
Still need help? Send us a message